New vaccines for Mammalian allergy using molecular approaches

about

Sensitization to Common and Uncommon Pets or Other Furry Animals: Which May Be Common Mechanisms?The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases.

P2860

Q37016918-E541B2D4-7DEC-4BDC-BAF1-B4461E1A8073 Q38259275-6B1E8B2A-C9C2-408C-BA8B-8562C6B181C8

P2860

New vaccines for Mammalian allergy using molecular approaches

Item

http://www.wikidata.org/entity/Q26998820

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

New vaccines for Mammalian allergy using molecular approaches

@ast

New vaccines for Mammalian allergy using molecular approaches

@en

New vaccines for Mammalian allergy using molecular approaches

@nl

type

Item

label

New vaccines for Mammalian allergy using molecular approaches

@ast

New vaccines for Mammalian allergy using molecular approaches

@en

New vaccines for Mammalian allergy using molecular approaches

@nl

prefLabel

New vaccines for Mammalian allergy using molecular approaches

@ast

New vaccines for Mammalian allergy using molecular approaches

@en

New vaccines for Mammalian allergy using molecular approaches

@nl

P1476

New vaccines for Mammalian allergy using molecular approaches

@en

P2093

Gabrielle Pauli

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of engineered allergen-specific immunotherapy vaccines

Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment

Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I

1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.

In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity

A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

New routes for allergen immunotherapy.

Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.

From allergen genes to allergy vaccines.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2014.00081

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marianne van Hage

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261140935

http://www.w3.org/2001/XMLSchema#string

P698

24672521

http://www.w3.org/2001/XMLSchema#string

P932

3954059

http://www.w3.org/2001/XMLSchema#string

New vaccines for Mammalian allergy using molecular approaches

about

P2860

P2860

New vaccines for Mammalian allergy using molecular approaches

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932